pyrimethamine has been researched along with Emesis in 10 studies
Maloprim: contains above 2 cpds
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 9.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| "Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1." | 9.07 | Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate." | 7.85 | Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017) |
| "The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children." | 7.67 | A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985) |
| " RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration." | 7.01 | Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023) |
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 5.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| "Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1." | 5.07 | Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate." | 3.85 | Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017) |
| "The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children." | 3.67 | A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985) |
| " RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration." | 3.01 | Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023) |
| " No significant adverse event attributable to any of the study drugs was found." | 2.73 | Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. ( Dama, S; Dembele, D; Dicko, A; Djimdé, AA; Doumbo, OK; Fofana, B; Ouologuem, D; Sagara, I; Sidibe, B; Toure, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muthoka, EN | 1 |
| Usmael, K | 1 |
| Embaye, SM | 1 |
| Abebe, A | 1 |
| Mesfin, T | 1 |
| Kazembe, D | 1 |
| Ahmedin, M | 1 |
| Namuganza, S | 1 |
| Kahabuka, M | 1 |
| Atim, MG | 1 |
| Manyazewal, T | 1 |
| González, R | 2 |
| Pons-Duran, C | 2 |
| Piqueras, M | 2 |
| Aponte, JJ | 2 |
| Ter Kuile, FO | 3 |
| Menéndez, C | 2 |
| Kakuru, A | 1 |
| Jagannathan, P | 1 |
| Muhindo, MK | 1 |
| Natureeba, P | 1 |
| Awori, P | 1 |
| Nakalembe, M | 1 |
| Opira, B | 1 |
| Olwoch, P | 1 |
| Ategeka, J | 1 |
| Nayebare, P | 1 |
| Clark, TD | 1 |
| Feeney, ME | 1 |
| Charlebois, ED | 1 |
| Rizzuto, G | 1 |
| Muehlenbachs, A | 1 |
| Havlir, DV | 1 |
| Kamya, MR | 1 |
| Dorsey, G | 1 |
| Lee, SJ | 1 |
| Price, RN | 1 |
| Luxemburger, C | 2 |
| Nosten, F | 2 |
| Maiga, AS | 1 |
| Diakite, M | 1 |
| Diawara, A | 1 |
| Sango, HA | 1 |
| Coulibaly, CO | 1 |
| Djimdé, AA | 1 |
| Fofana, B | 1 |
| Sagara, I | 1 |
| Sidibe, B | 1 |
| Toure, S | 1 |
| Dembele, D | 1 |
| Dama, S | 1 |
| Ouologuem, D | 1 |
| Dicko, A | 1 |
| Doumbo, OK | 1 |
| ter Kuile, F | 1 |
| Chongsuphajaisiddhi, T | 1 |
| Webster, HK | 1 |
| Edstein, M | 1 |
| Phaipun, L | 1 |
| Thew, KL | 1 |
| White, NJ | 1 |
| Bradley-Moore, AM | 1 |
| Greenwood, BM | 1 |
| Bradley, AK | 1 |
| Akintunde, A | 1 |
| Attai, ED | 1 |
| Fleming, AF | 1 |
| Bartlett, A | 1 |
| Bidwell, DE | 1 |
| Voller, A | 1 |
| Kirkwood, BR | 1 |
| Lazar, M | 1 |
| Weiner, MJ | 1 |
| Leopold, IH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546] | Phase 3 | 340 participants (Actual) | Interventional | 2020-08-31 | Completed | ||
| Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447] | Phase 3 | 300 participants (Actual) | Interventional | 2014-06-23 | Completed | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.022 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.024 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.000 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.035 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.000 |
Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.043 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.036 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.089 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.082 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.043 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.87 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.88 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.83 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 1.24 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.64 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.26 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.30 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.00 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.43 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.03 |
Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination
| Intervention | events per person years (Number) |
|---|---|
| Mothers - 3 Dose SP | 0.95 |
| Mothers - 3 Dose DP | 0.31 |
| Mothers - Monthly DP | 0 |
Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 19 |
| Mothers - 3 Dose DP | 19 |
| Mothers - Monthly DP | 9 |
Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination
| Intervention | hemoglobin measurements taken every 12wk (Number) |
|---|---|
| Mothers - 3 Dose SP | 94 |
| Mothers - 3 Dose DP | 72 |
| Mothers - Monthly DP | 61 |
Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 7 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 1 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 4 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0 |
Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Positive blood smears (Number) |
|---|---|
| Mothers - 3 Dose SP | 4 |
| Mothers - 3 Dose DP | 1 |
| Mothers - Monthly DP | 3 |
Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination
| Intervention | Positive specimens (Number) |
|---|---|
| Mothers - 3 Dose SP | 206 |
| Mothers - 3 Dose DP | 74 |
| Mothers - Monthly DP | 26 |
Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 59 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 25 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 7 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 52 |
| Monthly DP Pregnancy / Monthly DP Infancy | 4 |
Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 49 |
| Mothers - 3 Dose DP | 30 |
| Mothers - Monthly DP | 26 |
Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Micropscopic assessment of placental blood | LAMP assessment of placental blood | |
| Mothers - 3 Dose DP | 3 | 3 |
| Mothers - 3 Dose SP | 5 | 19 |
| Mothers - Monthly DP | 0 | 2 |
Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery
| Intervention | participants (Number) | |
|---|---|---|
| Microscopy | LAMP | |
| Mothers - 3 Dose DP | 1 | 3 |
| Mothers - 3 Dose SP | 5 | 25 |
| Mothers - Monthly DP | 0 | 1 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
3 reviews available for pyrimethamine and Emesis
| Article | Year |
|---|---|
Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials.
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant; Malaria; Pregnancy; Pregnancy Complication | 2023 |
Mefloquine for preventing malaria in pregnant women.
Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug | 2018 |
Mefloquine for preventing malaria in pregnant women.
Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum | 2018 |
4 trials available for pyrimethamine and Emesis
| Article | Year |
|---|---|
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
[Pharmacovigilance and impact of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women in Sélingué, Mali].
Topics: Adolescent; Adult; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Endemic D | 2010 |
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Biomarkers; Drug Combinations; Drug R | 2008 |
Mefloquine-resistant falciparum malaria on the Thai-Burmese border.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Drug Resist | 1991 |
3 other studies available for pyrimethamine and Emesis
| Article | Year |
|---|---|
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
Topics: Adolescent; Adult; Anorexia; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dizzi | 2017 |
A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children.
Topics: Antibodies; Chloroquine; Enzyme-Linked Immunosorbent Assay; Ferritins; Folic Acid; Hemodynamics; Hum | 1985 |
Treatment of uveitis with methotrexate.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Alopecia; Anti-Bacterial Agents; Child; | 1969 |